Technical Analysis for MATN - Mateon Therapeutics Inc

Grade Last Price % Change Price Change
grade A 0.26 -8.55% -0.0243
MATN closed down 8.55 percent on Friday, October 18, 2019, on 38 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical MATN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Wide Bands Range Expansion 0.00%
MACD Bullish Signal Line Cross Bullish -8.55%
NR7 Range Contraction -8.55%
Stochastic Reached Overbought Strength -8.55%
Wide Bands Range Expansion -8.55%
Overbought Stochastic Strength -8.55%

Older signals for MATN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Medicine Medical Specialties Cancer Clinical Medicine Biopharmaceutical Treatment Of Cancer Solid Tumors Tumor Cancer Treatments Angiology Angiogenesis Angiogenesis Inhibitor
Is MATN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.35
52 Week Low 0.05
Average Volume 25,399
200-Day Moving Average 0.171
50-Day Moving Average 0.2464
20-Day Moving Average 0.2668
10-Day Moving Average 0.2648
Average True Range 0.0486
ADX 11.31
+DI 14.3299
-DI 14.1973
Chandelier Exit (Long, 3 ATRs ) 0.2042
Chandelier Exit (Short, 3 ATRs ) 0.3558
Upper Bollinger Band 0.3118
Lower Bollinger Band 0.2218
Percent B (%b) 0.42
BandWidth 33.733133
MACD Line 0.0059
MACD Signal Line 0.0064
MACD Histogram -0.0005
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.3335
Resistance 3 (R3) 0.3387 0.3193 0.3213
Resistance 2 (R2) 0.3193 0.3006 0.3168 0.3172
Resistance 1 (R1) 0.2897 0.2891 0.3045 0.2845 0.3131
Pivot Point 0.2703 0.2703 0.2778 0.2678 0.2703
Support 1 (S1) 0.2407 0.2516 0.2555 0.2355 0.2069
Support 2 (S2) 0.2213 0.2401 0.2188 0.2028
Support 3 (S3) 0.1917 0.2213 0.1988
Support 4 (S4) 0.1865